CGENCompugen Ltd.Healthcare · Biotechnologyas of 2026-09-25
Horizon

Issued 2026-09-25 at $2.38 · now $2.38 (2026-09-25, +0.0% since)

Based on its own history, a month from the 2026-09-25 close, CGEN has typically landed between $1.74 and $3.28 — a range of −27.1% to +37.9% from the issuance price $2.38.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

5,008 overlapping 1 month windows · 2006-09-26 – 2026-08-26 · basis climatology · forecast (batch). Base rate up 53.7% (90% CI 51.5–55.9%, ≈1,391 obs). Not a call on this stock — we have no evidence its odds differ.

The cone is anchored at the 2026-09-25 issuance close ($2.38) — the price the forecast resolves against on 2026-10-26, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where CGEN has typically landed a month from the 2026-09-25 close of $2.38 — the range is history, not a prediction.

$1.74worst · -27.1%$3.28best · +37.9%
  • now $2.38 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $2.31 (-2.8%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.01–$2.62
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $1.74–$3.28
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 5,008 windows spanning 2006-09-26 to 2026-09-25. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2008-10-24−75.9%−75.9%+0.0%
2008-10-23−68.2%−68.2%+1.9%
2008-10-22−66.3%−66.3%+0.0%
3 best
2023-11-28+207.0%+0.0%+207.0%
2023-11-17+203.3%+0.0%+203.3%
2023-11-29+199.0%−1.3%+199.0%

5,008 overlapping windows · 2006-09-26 – 2026-09-25 · not cherry-picked

Pending catalysts

  • March 2027 — Trial primary completion: Phase 1/Phase PHASE2 primary completion: A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer (source, as of 2026-08-14)

Public, scheduled events — dated attention, not a prediction of the outcome. See the FDA catalysts page for the historical base rate.

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~20 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
75%
+15.2%
n=20
Feb
40%
−0.6%
n=20
Mar
50%
+0.7%
n=20
Apr
45%
+5.4%
n=20
May
40%
−0.6%
n=20
Jun
45%
+3.3%
n=20
Jul
45%
−1.1%
n=20
Aug
55%
+4.6%
n=20
Sep
45%
−2.4%
n=20
Oct
35%
−1.5%
n=20
Nov
45%
−2.8%
n=20
Dec
35%
+7.7%
n=20

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$3$12026-07-09: 1 insider sale, $5K — Levine Zurit2026-04-24: 2 insider sales, $22K — Ophir Eran, Levine Zurit2026-04-14: 2 insider sales, $20K — Ophir Eran, Levine Zurit2026-04-10: 1 insider sale, $8K — Levine Zurit2026-04-08: 1 insider sale, $13K — Levine Zurit2026-04-07: 1 insider sale, $6K — Levine Zurit2026-04-01: 2 insider sales, $20K — Ophir Eran, Levine Zurit2026-03-26: 1 insider sale, $24K — Levine Zurit2026-03: 1 open-market sale, $24K2026-04: 9 open-market sales, $89K2026-07: 1 open-market sale, $5K↑ buys↓ salesofficer Levine Zurit — Sale on 2026-07-09, filed 4 days after the tradedirector Ophir Eran — Sale on 2026-04-24, filed 3 days after the tradeofficer Levine Zurit — Sale on 2026-04-24, filed 3 days after the tradedirector Ophir Eran — Sale on 2026-04-14, filed 1 day after the tradeofficer Levine Zurit — Sale on 2026-04-14, filed 1 day after the tradeofficer Levine Zurit — Sale on 2026-04-10, filed 3 days after the tradeofficer Levine Zurit — Sale on 2026-04-08, filed 1 day after the tradeofficer Levine Zurit — Sale on 2026-04-07, filed 2 days after the tradedirector Ophir Eran — Sale on 2026-04-01, filed 2 days after the tradeofficer Levine Zurit — Sale on 2026-04-01, filed 2 days after the tradeofficer Levine Zurit — Sale on 2026-03-26, filed 4 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-07-09Levine ZuritofficerSale1,875 @ $2.50$5K−6.0% of holding−5.3%not yet — horizon still open29,375Form 4 · filed 4 days after the trade
2026-04-24Ophir ErandirectorSale5,000 @ $3.20$16K−30.5% of holding−19.6%not yet — horizon still open11,375Form 4 · filed 3 days after the trade
2026-04-24Levine ZuritofficerSale2,000 @ $3.20$6K−6.4% of holding−19.6%not yet — horizon still open29,375Form 4 · filed 3 days after the trade
2026-04-14Ophir ErandirectorSale5,000 @ $2.90$15K−30.5% of holding−7.9%not yet — horizon still open11,375Form 4 · filed 1 day after the trade
2026-04-14Levine ZuritofficerSale2,000 @ $2.80$6K−6.4% of holding−7.9%not yet — horizon still open29,375Form 4 · filed 1 day after the trade
2026-04-10Levine ZuritofficerSale3,125 @ $2.56$8K−9.6% of holding+2.4%not yet — horizon still open29,375Form 4 · filed 3 days after the trade
2026-04-08Levine ZuritofficerSale5,375 @ $2.42$13K−15.5% of holding+16.7%not yet — horizon still open29,375Form 4 · filed 1 day after the trade
2026-04-07Levine ZuritofficerSale2,500 @ $2.30$6K−7.8% of holding+7.6%not yet — horizon still open29,375Form 4 · filed 2 days after the trade
2026-04-01Ophir ErandirectorSale5,625 @ $2.21$12K−33.1% of holding+13.2%not yet — horizon still open11,375Form 4 · filed 2 days after the trade
2026-04-01Levine ZuritofficerSale3,500 @ $2.20$8K−10.6% of holding+13.2%not yet — horizon still open29,375Form 4 · filed 2 days after the trade
2026-03-26Levine ZuritofficerSale11,875 @ $2.04$24K−28.8% of holding+30.9%−4.3%29,375Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

49 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-07-29Mahler MichelleofficerAward / grant18,00018,000Form 4
2026-07-29Hukkelhoven MathiasdirectorAward / grant7,50017,500Form 4
2026-07-29Hukkelhoven MathiasdirectorAward / grant10,00010,000Form 4
2026-07-29Livnat Savitzky KinneretdirectorAward / grant7,50020,850Form 4
2026-07-29Livnat Savitzky KinneretdirectorAward / grant10,00010,000Form 4
2026-07-29Kredo Russo SharonofficerAward / grant18,00037,500Form 4
2026-07-29Kredo Russo SharonofficerAward / grant24,00024,000Form 4
2026-07-29Ferre PierreofficerAward / grant70,00070,000Form 4
2026-07-29Perry ErandirectorAward / grant7,50017,500Form 4
2026-07-29Perry ErandirectorAward / grant10,00010,000Form 4
2026-07-29Cohen-Dayag AnatdirectorAward / grant100,000100,000Form 4
2026-07-29Ophir ErandirectorAward / grant200,000200,000Form 4
2026-07-29Silberman DavidofficerAward / grant19,50055,000Form 4
2026-07-29Silberman DavidofficerAward / grant26,00026,000Form 4
2026-07-29Levine ZuritofficerAward / grant18,00047,375Form 4
2026-07-29Levine ZuritofficerAward / grant24,00024,000Form 4
2026-07-29Mahler MichelleofficerAward / grant13,50036,625Form 4
2026-07-29ZWEIFACH SANFORD SdirectorAward / grant7,50020,180Form 4
2026-07-29ZWEIFACH SANFORD SdirectorAward / grant10,00010,000Form 4
2026-07-29Halevy GileaddirectorAward / grant7,50018,907Form 4
2026-07-29Halevy GileaddirectorAward / grant10,00010,000Form 4
2026-07-09Levine ZuritofficerOption exercise1,87531,250Form 4
2026-07-09Levine ZuritofficerOption exercise1,8753,750Form 4
2026-04-24Ophir ErandirectorOption exercise5,00016,375Form 4
2026-04-24Levine ZuritofficerOption exercise2,00031,375Form 4
2026-04-24Ophir ErandirectorOption exercise5,00014,375Form 4
2026-04-24Levine ZuritofficerOption exercise2,00052,000Form 4
2026-04-14Ophir ErandirectorOption exercise5,00016,375Form 4
2026-04-14Levine ZuritofficerOption exercise2,00031,375Form 4
2026-04-14Ophir ErandirectorOption exercise5,00019,375Form 4
2026-04-14Levine ZuritofficerOption exercise2,00054,000Form 4
2026-04-10Levine ZuritofficerOption exercise2,00032,500Form 4
2026-04-10Levine ZuritofficerOption exercise1,12530,500Form 4
2026-04-10Levine ZuritofficerOption exercise2,00056,000Form 4
2026-04-10Levine ZuritofficerOption exercise1,1255,625Form 4
2026-04-08Levine ZuritofficerOption exercise4,37533,750Form 4
2026-04-08Levine ZuritofficerOption exercise1,00034,750Form 4
2026-04-08Levine ZuritofficerOption exercise1,00058,000Form 4
2026-04-08Levine ZuritofficerOption exercise4,3756,750Form 4
2026-04-07Levine ZuritofficerOption exercise2,50031,875Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.